New Directors Elected to California Healthcare Institute Board.

LA JOLLA, Calif. -- The California Healthcare Institute (CHI) today announced the election of Hans Bishop, head of the Hematology/Cardiology Business Unit of Bayer HealthCare Pharmaceuticals, based in Berkeley, Calif., and Catherine J. "Kitty" Mackey, Ph.D., senior vice president of Pfizer

Global Research and Development, site director of Pfizer's research and development site in La Jolla, Calif., and leader of Pfizer's external research network for the Western U.S. region to its board of directors. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

Hans Bishop oversees the development and commercialization of a diverse portfolio of products for treating diseases involving blood coagulation and thrombosis for Bayer HealthCare Pharmaceuticals. Bishop has more than 18 years of pharmaceutical industry experience. Prior to joining Bayer, he was the senior vice president of global commercial operations at Chiron Corporation Ltd. Bishop also served in roles of increasing responsibility that included sales and marketing and business development at Glaxo Wellcome and SmithKline Beecham. Previously, he spent four years as the executive vice president of operations with a global telecom service company, where he managed nine subsidiaries on three continents, before facilitating the sale of the company in 2004. Bishop earned his Bachelor of Science degree in chemistry from Brunel University in London, England.

Kitty Mackey has more than 25 years of experience in the fields of pharmaceutical research and development, as well as agricultural biotechnology. Since 2001, Mackey has served as site director of Pfizer La Jolla - a 1-million-square-foot research and development campus with more than 1,000 scientists and support staff focused on the discovery and development of innovative medicines for cancer and blindness. In 2007, she was assigned additional responsibility to lead Pfizer's external research network for the Western U.S. region. She began her career in agricultural biotechnology - initially with Pfizer in 1983, then DEKALB in 1990 and ultimately with Monsanto in 1998 - and led the discovery and development of several breakthrough technologies and products. In 1999, Mackey returned to Pfizer in Groton, Conn., to lead genomics, biomarker and pharmacogenomics research for human health. The next year, she assumed a leadership position with Pfizer's Strategic Alliances Group. Mackey received her Bachelor of Science and doctoral degrees in microbiology from Cornell University.

"We are pleased to add these experienced industry leaders to our board, better enabling us to represent the interests of our membership," said David L. Gollaher, Ph.D., CHI president and chief executive officer. "Both Hans and Kitty and their companies reflect our broad commitment to improving people's lives through biomedical innovation."

CHI represents more than 250 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's web site is www.chi.org.